ROG — ROGERS CORP
—
NYSE ·
Materials ·
Chemicals ·
CIK 84748 ·
Last close
$137.76
Market Cap
$2.46B
52W High
$169.00
52W Low
$75.14
ADV30
206,880
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 216,800,000 | 70,400,000 | 20,700,000 | 13,600,000 | 1,446,400,000 | 181,400,000 | 241,700,000 |
| Mar 2026 | 200,500,000 | 64,600,000 | 16,600,000 | 4,500,000 | 1,426,500,000 | 195,800,000 | 233,800,000 |
| Dec 2025 | 201,500,000 | 63,500,000 | 15,100,000 | 4,600,000 | 1,429,900,000 | 197,000,000 | 234,200,000 |
| Sep 2025 | 216,000,000 | 72,300,000 | 22,800,000 | 8,600,000 | 1,446,000,000 | 167,800,000 | 243,300,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$106,000,000
Investing CF
$-51,700,000
Financing CF
$-28,900,000
CapEx
$-23,200,000
Dividends Paid
—
Buybacks
$-52,400,000
EPS Diluted TTM
$1.75
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$1,137,400,000
Inventory
$130,000,000
Receivables
$181,000,000
ST Investments
$30,000,000
EBIT TTM
$59,900,000
Pretax Income TTM
$58,500,000
Interest Exp TTM
$1,400,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$834,800,000
EBITDA
$128,800,000
Free Cash Flow
$99,825,000
Enterprise Value
$2,259,344,128
Total Cash
$211,400,000
Total Debt
$28,500,000
Shares Out
17,868,335
Trailing EPS
$1.69
Book Value
$67.30
ROE
2.6%
ROA
3.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 810,800,000 | 52,100,000 | -61,800,000 | 1,429,900,000 | 234,200,000 | 1,195,700,000 | 101,200,000 |
| Dec 2024 | 830,100,000 | 49,100,000 | 26,100,000 | 1,481,100,000 | 229,500,000 | 1,251,600,000 | 127,100,000 |
| Dec 2023 | 908,400,000 | 69,100,000 | 56,600,000 | 1,517,200,000 | 258,200,000 | 1,259,000,000 | 131,400,000 |
| Dec 2022 | 971,200,000 | 67,000,000 | 116,600,000 | 1,646,200,000 | 473,700,000 | 1,172,500,000 | 129,500,000 |
TTM Snapshot
Revenues TTM
$877,131,000
NetIncome TTM
$43,138,000
OpCashFlow TTM
$0
Assets (Latest)
$1,429,900,000
Forward EPS
$4.45
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $120.00 · spot: $137.76 · call volume: 85 · put volume: 31Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOSP | INNOSPEC INC. | $2.43B | $98.72 | — |
| NGVT | Ingevity Corp | $2.51B | $73.00 | — |
| CURLF | Curaleaf Holdings, Inc. | $2.59B | $11.07 | — |
| COTY | COTY INC. | $2.33B | $2.65 | — |
| WDFC | WD 40 CO | $2.67B | $199.17 | — |
News headlines (Yahoo Finance, 1h cache)
Rogers (ROG) Stock Looks Overvalued After Its 73% Rise
2026-09-25 03:12 · Yahoo
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
2026-09-15 09:40 · Yahoo
Rogers Corporation Announces Investor Day on September 30, 2026
2026-09-09 20:38 · Yahoo
3 Small-Cap Stocks We Find Risky
2026-09-24 11:36 · Yahoo
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
2026-09-23 05:15 · Yahoo
Change in Roche’s Board of Directors
2026-09-23 05:00 · Yahoo
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
2026-09-22 05:00 · Yahoo
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
2026-09-21 15:45 · Yahoo
3 Low-Volatility Stocks We Find Risky
2026-09-21 07:42 · Yahoo
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
2026-09-18 10:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.